Retrospective Cohort Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 26, 2024; 12(27): 6057-6069
Published online Sep 26, 2024. doi: 10.12998/wjcc.v12.i27.6057
Prognostic factors of early recurrence after complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Chao-Yu Chen, Tzu-Hao Huang, Li-Wen Lee, Jrhau Lung, Yu-Che Ou, Chien-Hui Hung, Huei-Chieh Chuang, Min-Chi Chen, Ting-Yao Wang
Chao-Yu Chen, Yu-Che Ou, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Chiayi 613, Taiwan
Chao-Yu Chen, Chien-Hui Hung, Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Chao-Yu Chen, Ting-Yao Wang, Department of Early Childhood Care and Education, Shu-Zen Junior College of Medicine and Management, Kaohsiung 821, Taiwan
Tzu-Hao Huang, Division of General Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan
Li-Wen Lee, Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Chiayi 613, Taiwan
Li-Wen Lee, Jrhau Lung, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
Jrhau Lung, Department of Medical Research and Development, Chang Gung Memorial Hospital, Chiayi 613, Taiwan
Yu-Che Ou, Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan
Huei-Chieh Chuang, Department of Anatomic Pathology, Chang Gung Memorial Hospital, Chiayi 613, Taiwan
Min-Chi Chen, Department of Public Health, Chang Gung University, Taoyuan 333, Taiwan
Ting-Yao Wang, Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi 613, Taiwan
Author contributions: Chen CY and Wang TY designed the research; Chen CY, Chen MC, and Lung J conducted the research; Chen MC and Wang TY analyzed the data; Chen CY, Wang TY, and Chen MC wrote the paper; Huang TH, Lee LW, Ou YC, Hung CH, and Chuang HC provided critical revision of the manuscript; Chen CY had primary responsibility for final content; and all authors read and approved the final manuscript.
Supported by the Chang Gung Medical Foundation, No. CMRPG6L0091, No. CMRPG6L0092, and No. CMRPG6L0093.
Institutional review board statement: The study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (Approval No. 202001607A3).
Informed consent statement: The Institutional Review Board of Chang Gung Memorial Hospital approves the waiver of the informed consent form.
Conflict-of-interest statement: The authors have no relevant financial or non-financial interests to disclose.
Data sharing statement: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ting-Yao Wang, MD, Chief Physician, Division of Hematology and Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, No. 8 Sec. W. Jiapu Road, Chiayi 613, Taiwan. tywang.onco@gmail.com
Received: June 4, 2024
Revised: June 25, 2024
Accepted: July 15, 2024
Published online: September 26, 2024
Processing time: 54 Days and 18.2 Hours
Core Tip

Core Tip: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can extend survival in peritoneal carcinomatosis, but outcomes vary. This study examined factors affecting progression-free survival (PFS) after CRS/HIPEC in patients with colorectal, high-grade appendiceal, ovarian, and gastric cancers. Evaluating the results of 80 patients from 2015-2020 showed that those with a completeness of cytoreduction score of 0 (CC-0) or surgery duration ≤ 6 h had better PFS. Achieving CC-0 was the key predictor of favorable PFS and longer overall survival. The study highlights the importance of patient selection for optimal CRS/HIPEC outcomes.